

Clinical Trial Protocol

Iranian Registry of Clinical Trials

18 Sep 2026

A comparative study of the therapeutic effect of topical finasteride with oral finasteride in patients with androgenetic alopecia .

Protocol summary

Study aim

Determination and comparison of the therapeutic effect of topical finasteride with oral finasteride in patients with androgenetic alopecia.

Design

The study is a randomized, controlled, blinded investigator, phase 3 trial parallel (assignment of two groups). restricted randomization method, the permuted block randomization type will be used, and a random sequence will be created using the random allocation software. Replacement blocks of 4 are assigned to two treatments (groups A, b). At least 14 people were considered for each group.

Settings and conduct

Patients are randomly selected from patients who refer to the dermatology clinic of Shahid Faqihi in Shiraz and receive drug treatment for 6 months and are examined after 3 months and at the end of 6 months. The collection tool in this study is a checklist that the results of the treatment evaluation will be recorded at the beginning of the study, at the end of the 3rd and 6th month. The assessment of the process of improving hair growth from the point of view of the patient and the doctor based on clinical judgment in terms of hair density (weak and medium and good and excellent) will be done

Participants/Inclusion and exclusion criteria

inclusion: Having androgenic alopecia grade 2 to 5 based on the Norwood Hamilton classification in men: age above 18 years, having androgenic alopecia grade 2 to 3 according to ludwig grading in women: menopausal women or women over 18 years of age who use IUD or TL: informed consent to participate in the study exclusion: history of allergic reaction to finasteride drug: pregnancy or trying to have a child: active infection or any scratches and wounds in the scalp

Intervention groups

Group A will use finasteride in oral form and group B will use the topical form of finasteride nano liposomal

solution 0.1% once a day.

Main outcome variables

The rate of improvement of hair loss; dht serum level

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20220901055844N1**

Registration date: **2023-12-19, 1402/09/28**

Registration timing: **prospective**

Last update: **2023-12-19, 1402/09/28**

Update count: **0**

Registration date

2023-12-19, 1402/09/28

Registrant information

Name

Roya Radanfar

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 71 3230 1542

Email address

roya.radanfar72@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2024-01-10, 1402/10/20

Expected recruitment end date

2024-08-02, 1403/05/12

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date
empty

Scientific title
A comparative study of the therapeutic effect of topical finasteride with oral finasteride in patients with androgenetic alopecia .

Public title
A comparative study of the therapeutic effect of topical finasteride with oral finasteride in patients with androgenetic alopecia .

Purpose
Treatment

Inclusion/Exclusion criteria
Inclusion criteria:
Having androgenic alopecia grade 2 to 5 based on the Norwood Hamilton classification in men Age above 18 years Not receiving treatment for androgenic alopecia during the last 3 months Having androgenetic alopecia grade 2 to 3 according to Ludwig grading in women Menopausal women or women over 18 years of age who use IUD or TL. Informed consent to participate in the study
Exclusion criteria:
Failure to sign the consent form. History of allergic reaction and anaphylaxis to Finasteride drug Pregnancy or trying to have a child. Individual history of infertility Active infection or any scratches and wounds in the scalp

Age
From **18 years** old

Gender
Both

Phase
3

Groups that have been masked

- Investigator

Sample size
Target sample size: **28**

Randomization (investigator's opinion)
Randomized

Randomization description
The design will be done in parallel (assignment of two groups). The randomization of the design will be done by the restricted randomization method, the permuted block randomization type will be used, and a random sequence will be created using the random allocation software. Replacement blocks of 4 are assigned to two treatments (groups A, b). So that at least 14 people are treated with oral finasteride and at least 14 people are treated with topical finasteride.

Blinding (investigator's opinion)
Single blinded

Blinding description
Blinding will be done in such a way that two types of drugs will be provided to the patients by the second colleague of the resident of the project, and the collection of information before, three months after and 6 months after will be done by the resident of the project, who is not aware of the type of drug. Plan; The

data with the name of the group will be provided to the consultant professor

Placebo
Not used

Assignment
Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of Shiraz University of Medical Sciences

Street address

Shahid fagihi hospital, zand ave, Shiraz

City

Shiraz

Province

Fars

Postal code

7134846114

Approval date

2023-04-15, 1402/01/26

Ethics committee reference number

IR.SUMS.MED.REC.1402.031

Health conditions studied

1

Description of health condition studied

Androgenic alopecia

ICD-10 code

L64

ICD-10 code description

Androgenic alopecia

Primary outcomes

1

Description

The rate of improvement in hair growth

Timepoint

evaluating the improvement of hair loss at the beginning of the study and at the end of 3months and at the end of 6months

Method of measurement

Comparison of the effect of topical finasteride with oral finasteride in the treatment of androgenic hair loss. how to measure this variable is with a questionnaire.

2

Description

Serum Dihydrotestosterone

Timepoint

At the beginning of the study and at the end of 6 months

Method of measurement

by free blood sampling from the patient at the Motahari clinic in Shiraz by use a lab kit to measure blood Dihydrotestosterone

3

Description

Investigation of drug side effects

Timepoint

At the end of the 3rd month and the end of the 6th month

Method of measurement

At each stage, unwanted side effects, including redness, itching and symptoms of drug reaction, as well as breast tenderness, and symptoms of sexual dysfunction, are asked from the patients and recorded in the questionnaire.

Secondary outcomes

empty

Intervention groups

1

Description

Intervention group: In group A, finasteride drug in oral form will be used. In this group, finasteride 1 mg tablets will be prescribed daily for male patients and 5 mg tablets manufactured by Ati Pharmed pharmaceutical company for female patients. In group B, the topical form of finasteride nano liposomal solution 0.1% will be used once a day. Finasteride nanoliposomes were prepared using the formulation prepared in the approved design and thesis of Dr. Mehyar Dari Gio under number 940768 at Mashhad University of Medical Sciences. will be. Then the properties of finasteride-containing nanoliposomes including particle size and zeta potential by DLS device. Morphology will be checked by electron microscope and stability on day 0, 1, 3, 6, 12 and 24 months at ambient temperature and 4 degrees, 25 and 37 degrees (according to ICH protocol.) which is sprayed on the surface of the area by the plastic applicator that comes with the product and massaged gently. Also, the patient will be warned not to wash the area for several hours after use, and to spray a little amount on the scalp and avoid a large amount. In order to use the same drug for the same patient on different days or for different patients, standard sprays were used, where every 12 to 15 puffs is equivalent to using 1 ml of the desired lotion. The duration of treatment in both groups is 6 months. And the visits of patients in both groups will be done at the beginning of the study and in the 3rd month and in the 6th month. Medicines are sent to the laboratory of Motahari Clinic in Shiraz for blood sampling, and the serum DHT levels will be checked for free before and after the start of treatment and after the end of 6 months of treatment. In order to comply with the

blinding in the study, the resident is responsible for visiting and following up the response to the treatment in two groups and collecting information, they will not know the type of treatment given to the patients.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Dermatology clinic, Shahid Faghihi Hospital

Full name of responsible person

Roya Radanfar

Street address

Shahid Faghihi Hospital, Zand Ave, Shiraz

City

Shiraz

Province

Fars

Postal code

7134846114

Phone

+98 915 035 1139

Email

Roya.Radanfar72@gmail.com

Web page address

<https://faghihi.sums.ac.ir>

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Shiraz University of Medical Sciences

Full name of responsible person

Mohammadhashem Hashempur

Street address

Shahid Faghihi Hospital, Zand Ave, Shiraz

City

Shiraz

Province

Fars

Postal code

7134846114

Phone

+98 71 3235 7282

Email

hashempurm@sums.ac.ir

Web page address

<https://faghihi.sums.ac.ir>

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Shiraz University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Shiraz University of Medical Sciences

Full name of responsible person

Mehdi Ghahartars

Position

Assistant professor

Latest degree

Specialist

Other areas of specialty/work

Dermatology

Street address

Shahid Faghihi Hospital, Zand Ave, Shiraz

City

Shiraz

Province

Fars

Postal code

7134846114

Phone

+98 917 313 9214

Email

Mehdighahartars@yahoo.com

Web page address

<https://faghihi.sums.ac.ir>

Person responsible for scientific inquiries

Contact

Name of organization / entity

Shiraz University of Medical Sciences

Full name of responsible person

Roya Radanfar

Position

Resident

Latest degree

Medical doctor

Other areas of specialty/work

Dermatology

Street address

Shahid Faghihi Hospital, Zand Ave, Shiraz

City

Shiraz

Province

Fars

Postal code

7134846114

Phone

+98 915 035 1139

Email

Roya.Radanfar72@gmail.com

Web page address

<https://faghihi.sums.ac.ir>

Person responsible for updating data

Contact

Name of organization / entity

Shiraz University of Medical Sciences

Full name of responsible person

Roya Radanfar

Position

Resident

Latest degree

Medical doctor

Other areas of specialty/work

Dermatology

Street address

Shahid Faghihi Hospital, Zand Ave, Shiraz

City

Shiraz

Province

Fars

Postal code

7134846114

Phone

+98 915 035 1139

Email

Roya.Radanfar72@gmail.com

Web page address

<https://faghihi.sums.ac.ir>

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Yes - There is a plan to make this available

Data Dictionary

Yes - There is a plan to make this available

Title and more details about the data/document

The results of the study are shared

When the data will become available and for how long

The access period starts 6 months after the results are published

To whom data/document is available

The data of the study is made available to all people who are engaged in this industry

Under which criteria data/document could be used

There are no conditions

From where data/document is obtainable

via email Roya.Radanfard72@gmail.com
What processes are involved for a request to access data/document

From the time of sending the request by email for one month
Comments